Very often the first several solutions tested on humans are not ideal and lead to other solutions that also take a few years to develop and test.
Mostly true True in substance, wrong in a detail.
Factual: Statements about the present or the past, checked against the record: did they hold up?
The second judge said mixed; the verdict shown is the first judge's.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
Judge as of 2020. True: evidence shows that early candidates tested in humans very often fail or prove suboptimal, leading to follow-on candidates that take years to develop (e.g., high clinical attrition rates, with roughly 90% of candidates failing). Mostly true: the general pattern holds, but 'a few years' for follow-ons is somewhat imprecise. Mixed: attrition is high, but evidence that failures typically lead to multi-year follow-on development is weak. Mostly false: the pattern applies only in narrow areas and is stated as general. False: most first candidates succeed, or follow-ons are quick.
Set before the research began.
Evidence (4)
-
E1 Need for NAMs: A systematic evidence synthesis revealing over half a century of drug development failure PMC (NCBI) · 21 July 2026
“Success rates in drug development are notoriously low, with fewer than 1 out of 10 drug candidates that enter clinical trials gaining marketing approval (Dowden and Munro, 2019; Thomas et al., 2021).”
-
E2 Need for NAMs: A systematic evidence synthesis revealing over half a century of drug development failure PMC (NCBI) · 21 July 2026
“The earliest failure rate in our dataset describes the attrition of 211 compounds evaluated in clinical trials between 1963 and 1965, with a calculated failure rate of 90.5% (Sheck et al., 1984).”
-
E3 Estimation of clinical trial success rates and related parameters Biostatistics (Oxford Academic) · April 2019
“For example, oncology has a 3.4% success rate in our sample vs. 5.1% in prior studies.”
-
E4 Publication of Drug Failures in Late-Stage Clinical Development JAMA Internal Medicine · 1 December 2016
“Among 640 novel therapeutics, 344 (54%) failed in clinical development, 230 (36%) were approved by the US Food and Drug Administration (FDA), and 66 (10%) were approved in other countries but not by the FDA.”
Reasoning
Independent sources show high clinical attrition: E1 reports that fewer than 1 in 10 candidates entering clinical trials gain approval, E2 records a 90.5% failure rate as early as the 1960s, E3 gives a 3.4% oncology success rate, and E4 finds 54% of 640 novel therapeutics failed in clinical development. This matches the attrition pattern the criteria cite as support for the claim. None of the evidence directly documents that failures lead to follow-on candidates taking a few years, so that part is somewhat imprecise and the claim is rated mostly true rather than true.
Cite this claim
Ray Kurzweil, “Very often the first several solutions tested on humans are not ideal and lead to other solutions that also take a few years to develop and test.” (said May 2020). Verdict: mostly true. Reliability API, claim c_34521b7d8319, method 0.1.0+28da144b, dataset release v1.1.2. https://epistacklabs.com/claims/c_34521b7d8319
This claim is in dataset release v1.1.2, with the same verdict.
Reply to this claim
More factual claims by Ray Kurzweil
-
Mostly false
“Right now, you’re getting back about four months a year.”
Currently scientific progress gives back about four months of life expectancy per year.
-
Mostly false
“And then AlphaFold 2 in 2022 went through 200 million proteins and got the shape exactly correct, and that’s going to help come up with new medications.”
-
Resolved true
“As of two or three years ago, we had gone through 170,000 proteins.”
As of two or three years ago, 170,000 proteins had been worked through by people.
-
Mixed
“The current method for testing these few treatments is to organize a few hundred human subjects and then test them over about a year and a half, at a cost of hundreds of millions of dollars.”
-
Mostly true
“Argonne National Lab has used five of the world’s most powerful supercomputers to narrow a billion molecules down to a few thousand.”
Verdicts are made automatically; how verdicts are made.